NCT07497282Not yet recruitingPhase 2
Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis
The Effect of Venlafaxine as an Adjunct Therapy on The Clinical Outcome of Rheumatoid Arthritis Patients
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation of the joints, leading to pain, swelling, disability, and reduced quality of life. Current therapies, although effective, may have limited efficacy or tolerability in some patients. Biological DMARDs are often associated with adverse effects, including increased risk of serious infections and heart failure. Long-term use may also increase the risk of malignancies. These limitations, together with their high cost. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), has shown potential anti-inflammatory properties in addition to its antidepressant effects. This study aims to evaluate the efficacy and safety of venlafaxine as an adjunct therapy in the management of rheumatoid arthritis.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 19 Jan 2026
- Start date
- Mar 2026
- Primary completion date
- Oct 2026
- Lead sponsor
- Ain Shams University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07497282
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 70
- From Mar 2026 to the primary completion date, Oct 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving biologics or targeted DMARDs
- Concurrent Use of MAOIs
- Patients receiving any other anti-depressant
Other illness
- Known hypersensitivity to venlafaxine or any of its components.
- Uncontrolled hypertension
- Unstable Heart Conditions
- Psychiatrically unstable patients as indicated by a history of psychosis or mania, current suicidal ideation, current substance abuse or dependence.
- Patients with active major bleeding or high risk of bleeding
Lab values
- Renal dysfunction (creatinine clearance \<60 mL/min)
- Hepatic dysfunction (ALT and AST more than 3 times upper normal limits)
Other
- Women who are pregnant or breastfeeding.
Who the study is looking for
- Adult patients with definite RA according to ACR/ EULAR 2010 criteria.
- Patients on stable DMARDs+/- steroid regimen for at least 6 months.
- Patients with moderate to high disease activity (DAS28 ≥ 3.2) despite treatment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.